Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

BioCancell Surges Most in Three Months on Cancer Trial Results

March 14 (Bloomberg) -- BioCancell Therapeutics Inc. jumped the most in three months after the biotechnology company said the results of ovarian cancer trials for its BC-819 treatment support the expansion of the clinical trials.

The shares advanced as much as 8.8 percent, the biggest gain since Dec. 11, to 0.84 shekel. It was at 0.82 shekel at 2:25 p.m. in Tel Aviv, giving the Jerusalem-based company a market value of 32.3 million shekels ($8.5 million).

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.